Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.

Clinical trial NCT06393361 · RECRUITING

Trial details

NCT number: NCT06393361
Sponsor: Chinese PLA General Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma

Start date: 2024-06-01
Primary completion: 2027-06-01
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.